Luxeptinib is primarily investigated for its use in targeted cancer therapy, particularly in hematologic malignancies. It functions as a selective kinase inhibitor, modulating key signaling pathways involved in tumor cell proliferation and survival. Its application shows promise in treating certain types of lymphoma and leukemia, especially where other treatments have failed due to resistance or toxicity. Clinical studies focus on its efficacy in B-cell receptor pathway-driven cancers, leveraging its ability to inhibit specific kinases like BTK with high precision. This selectivity helps reduce off-target effects, improving patient tolerance and enabling long-term dosing in chronic treatment regimens. Additionally, luxeptinib is being explored in combination therapies to enhance anti-tumor responses and overcome resistance mechanisms.